About
Technology
Issues
FAQ
Links
Official Page
TheraP: A randomised phase II trial of
177
Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.